Welcome to our dedicated page for Healthequity SEC filings (Ticker: HQY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HealthEquity, Inc. filings document regulatory disclosures for an HSA custodian and consumer-directed benefits administrator. Recent 8-K reports cover operating results and financial condition, guidance furnished under Regulation FD, HSA account and asset metrics, revenue categories, stock repurchase activity, and hedging used to reduce HSA cash repricing risk.
Governance filings record board appointments and committee assignments, annual meeting vote results, auditor ratification, advisory executive compensation votes, executive employment agreement amendments, severance arrangements, equity award terms, and technology-organization leadership responsibility. These disclosures frame the company's capital allocation, compensation governance, risk oversight and public-company reporting obligations.
HEALTHEQUITY, INC. executive vice president and chief commercial officer Michael Henry Fiore reported an open-market sale of 3,142 shares of common stock at $95.00 per share. After this transaction, he directly holds 59,113 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person.
HEALTHEQUITY, INC. director Gayle Furgurson exercised stock options and sold shares in a pre-planned transaction. She exercised options to acquire 2,439 shares of common stock at an exercise price of $47.21 per share, then sold 2,439 shares in an open-market transaction at $90.00 per share. These transactions were executed under a Rule 10b5-1 trading plan adopted on January 14, 2026, indicating they were pre-scheduled. Following the transactions, she holds 19,733 shares of HealthEquity common stock directly, and the exercised option covering 2,439 shares is now fully used.
HEALTHEQUITY, INC. executive Delano Ladd, EVP and General Counsel, sold 7,500 shares of Common Stock in an open-market transaction on May 28, 2026 at $90.00 per share. The sale was made under a Rule 10b5-1 trading plan adopted on June 12, 2025. Following this transaction, Ladd directly holds 91,141 shares of HealthEquity common stock.
HealthEquity, Inc. reported quarterly revenue of $354.6 million for the three months ended April 30, 2026, up 7% from a year earlier, driven mainly by an 11% increase in custodial revenue and growth in service and interchange revenue. Net income rose to $69.4 million from $53.9 million, and diluted earnings per share increased to $0.82. Adjusted EBITDA reached $164.5 million, or 46% of revenue, reflecting lower service costs from technology efficiencies.
The company administered 10.6 million HSAs and 7.2 million complementary consumer-directed benefits, with total HSA Assets of $37.1 billion, up 19%. It repurchased 1.5 million shares for $123.0 million and prepaid $15.0 million on its revolving credit facility, leaving long-term debt at $942.7 million. A $34.3 million pre-tax loss on Treasury bond forward hedges reduced accumulated other comprehensive income, but operating cash flow remained strong at $97.5 million.
HealthEquity reported strong results for the quarter ended April 30, 2026, with revenue of $354.6 million, up 7% year over year. Net income rose 29% to $69.4 million, lifting net margin to 20%, while Adjusted EBITDA increased 17% to $164.5 million, or a 46% margin.
Total HSA Assets reached $37.1 billion, up 19%, including $19.6 billion in HSA investments as more members invest their balances. The company repurchased 1.5 million shares for $123.0 million and its board authorized an additional $1.0 billion for future buybacks.
For the fiscal year ending January 31, 2027, management now expects revenue of $1.410 billion to $1.420 billion, net income of $242 million to $248 million (diluted EPS of $2.88 to $2.95), non-GAAP diluted EPS of $4.66 to $4.73, and Adjusted EBITDA of $625 million to $633 million.
HealthEquity, Inc. is asking stockholders to vote at a virtual annual meeting on June 25, 2026 on five key items, including electing ten directors, ratifying PricewaterhouseCoopers as auditor, an advisory say-on-pay vote, and approving a 2026 Employee Stock Purchase Plan and an amended 2024 Equity Incentive Plan.
The proxy highlights strong fiscal 2026 performance, with revenue of $1.313 billion, net income of $215.2 million and diluted EPS of $2.46, alongside Adjusted EBITDA of $566.0 million. Operationally, the company ended the year with 10.6 million health savings accounts, 17.8 million total accounts and $36.5 billion of HSA assets.
HealthEquity also reports repurchasing 3.3 million shares for $301.7 million and describes an extensive governance framework, including an independent chair, fully independent key committees, formal risk oversight (with a dedicated cybersecurity and technology committee), and a pay-for-performance executive compensation program emphasizing multi‑year, at‑risk equity, stock ownership guidelines, and a clawback policy.